Nuvectis Stock Surges Around 97% in 3 Months: Here's Why

Image Source: Zacks Investment Research

Haisco Deal Marks a Major Pipeline Expansion

A key catalyst came in June, when Nuvectis entered into an agreement with Haisco Pharmaceutical Group to acquire the ex-China rights to a rare-disease candidate NXP100 and an oncology candidate NXP200. The transaction significantly broadened Nuvectis’ pipeline and added two assets with potentially differentiated therapeutic applications.

The deal complemented NXP900, Nuvectis’ internally developed oncology program, with two new candidates that could provide additional near- and long-term value drivers.

NXP100 Adds a Late-Stage Commercial Opportunity

NXP100 is an oral, once-daily complement Factor B inhibitor designed to selectively block the alternative complement pathway. The candidate is being developed for complement-mediated diseases, including paroxysmal nocturnal hemoglobinuria (PNH), IgA nephropathy and C3 glomerulonephritis.

In July, NXP100 received approval in China under the brand name Ciprocopan for previously untreated PNH patients who had not previously received complement inhibitors. The approval provides clinical and regulatory validation of the drug’s mechanism and positions the company to advance NXP100 toward later-stage development and eventual commercialization in ex-China markets, creating a clearer path to value creation.

NXP200 Broadens the Oncology Opportunity

NXP200, the second asset acquired from Haisco, further strengthens Nuvectis’ oncology portfolio. NXP200 is an oral paradox breaker BRAF inhibitor targeting class I, II and III BRAF mutations. Unlike conventional BRAF inhibitors, NXP200 is designed to inhibit BRAF signaling while avoiding paradoxical activation associated with earlier-generation approaches. The program is being evaluated in oncology, including BRAF-mutant glioma and Nuvectis has presented preclinical research supporting its potential.

The strategic importance of NXP200 is that it gives the company another differentiated oncology asset along with NXP900. This could reduce the company’s reliance on a single oncology candidate and increase the potential value of its overall pipeline. U.S. regulatory activities for NXP200 are progressing, with the investigational new drug application filing anticipated in the fourth quarter of 2026.

NXP900 Remains an Important Catalyst

NXP900 is an oral SRC/YES1 kinase inhibitor with a differentiated Type 1.5 mechanism designed to inhibit both the catalytic and scaffolding functions of SRC-family kinases. NXP900 is being advanced in combination studies across non-small cell lung cancer (NSCLC) and pancreatic cancer. In NSCLC, data from the ongoing NXP900 plus osimertinib study is expected by year-end 2026, while a study combining NXP900 with lorlatinib in ALK-positive patients is expected to begin in the third quarter of 2026. In pancreatic cancer, an investigator-sponsored study evaluating NXP900 with daraxonrasib is planned at two U.S. medical centers, subject to FDA approval and drug availability.

NVCT’s Zacks Rank & Stocks to Consider

Nuvectis currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks in the biotech sector are Amneal Pharmaceuticals AMRX and Precigen PGEN, currently sporting a Zacks Rank #1 (Strong Buy) each, while AC Immune ACIU carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Over the past 30 days, earnings per share estimates for Amneal Pharmaceuticals have increased from $1.00 to $1.02 for 2026. Over the same period, estimates for earnings per share increased from $1.12 to $1.21 for 2027. AMRX shares have risen 44.4% year to date.

Amneal Pharmaceuticals beat earnings in each of the trailing four quarters, delivering an average surprise of 32.82%.

Over the past 30 days, estimates for Precigen’s 2026 loss per share have improved from a loss of 2 cents to earnings per share of 25 cents. Over the same period, earnings estimates for 2027 have risen from 25 cents to 86 cents. PGEN shares have increased 61.5% year to date.

Precigen’s earnings beat estimates in three of the trailing four quarters and missed in the remaining one, with the average surprise being 108.96%.

Over the past 30 days, estimates for AC Immune’s 2026 loss per share have narrowed from 84 cents to 60 cents. Over the same period, earnings estimates for 2027 remained unchanged at 17 cents. ACIU shares have declined 18.2% year to date.

AC Immune’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 33.25%.

Zacks' Research Chief Names "Stock Most Likely to Double"

Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.

This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research